Sleep Disorders

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 21, 2021.

The director of research at St. Luke’s Sleep Medicine and Research Center discussed the current treatment landscape for excessive daytime sleepiness and how solriamfetol plays a role.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 14, 2021.

The director of the sleep disorders center at Cleveland Clinic discussed the data on lower sodium oxybate presented at AAN 2021.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee, discussed the aim of his practice’s study.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 7, 2021.

Paula K. Schweitzer, PhD, discussed her findings on the safety and efficacy of solriamfetol in patients receiving OSA therapy and the need for more research on residual excessive daytime sleepiness.

Didactic lectures were the most commonly used teaching format by all specialties, with pulmonary and critical care medicine and neurology reporting the highest hours of attendance.

The neurologist at University of Utah discussed the potential of using teleneurology to diagnose neurological conditions.

The director of the sleep disorders center at Cleveland Clinic discussed her investigations into low-sodium oxybate presented at AAN 2021.

The director of research at St. Luke’s Sleep Medicine and Research Center detailed the reasons for residual excessive daytime sleepiness and the lack of literature on the topic.

Here's what is coming soon to NeurologyLive.

The World Sleep Society Narcolepsy Task Force surveyed clinicians in an effort to understand regional differences in the diagnosis and management of narcolepsy.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 30, 2021.

The director of research at St. Luke’s Sleep Medicine and Research Center discussed the motivation behind her study assessing solriamfetol in patient’s adherent and nonadherent to primary OSA therapy.

Investigators also studied how use of a patient engagement tool influenced adherence rates to PAP.

Researchers compared sleep measures between the Fitbit Charge 3, the Actigraph GT9X accelerometer, and polysomnography.

Changes in mean use of airway therapy from baseline to week 40 of the open-label extension were minimal for those on solriamfetol.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee, discussed findings from his study on PAP adherence.

Here's what is coming soon to NeurologyLive.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee discussed issues in caring for patients with OSA.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 23, 2021.